This Plain Language Summary of publication article (PLSP) from Future Oncology review summarizes two studies on relugolix combination therapy for advanced prostate cancer, which occurs when cancer spreads beyond the prostate. Relugolix, an oral medication that lowers testosterone, was combined with either novel hormonal therapies or chemotherapy. Researchers evaluated potential side effects and whether the combination therapy was as effective at lowering testosterone as relugolix alone.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer’ published in Targeted Oncology, and ‘Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer’ and was published in Clinical Genitourinary Cancer.

Visit Springer Nature using the link to read the original article.

Visit Clinical Genitourinary Cancer using the link to read the original article.